Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04404660 · ClinicalTrials.gov registry record · Phase 1
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
A Phase 1 study of Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, sponsored by Autolus Limited.
- Active
- Registry status
- Phase 1
- Development phase
- 153
- Enrollment target
- 20
- Study locations
NCT04404660: Active Phase 1 study of Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, sponsored by Autolus Limited.
NCT04404660 is a Phase 1 study of Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia that is active but no longer recruiting, run by Autolus Limited. The registered enrollment target is 153 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (155% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04404660, a Phase 1 study of Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, is active but no longer recruiting, sponsored by Autolus Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 153 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase Ib/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).
Conditions Studied
Interventions
- BIOLOGICAL AUTO1
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- University of California San Diego Health (UCSD) - La Jolla
- University of California Davis (UC Davis) - Sacramento
- University of California San Francisco (UCSF) - San Francisco
Florida
- University of Miami - Miami
- H Lee Moffitt Cancer Center - Tampa
New York
- Memorial Sloan Kettering Cancer Center - New York
- University of Rochester - Rochester
Colorado
- Colorado Blood Cancer Institute (CBCI) - Denver
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Illinois
- University of Chicago - Chicago
Kansas
- University of Kansas - Kansas City
Maryland
- University of Maryland Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2020-06-03 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 1 |
What the registry record for NCT04404660 still lists
NCT04404660 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (155% higher).
The record links to 1 condition, with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which AUTO1 is the first listed.
NCT04404660 names 20 study sites across 15 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT04404660 about?
NCT04404660 is a clinical study titled "A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)". This is a Phase Ib/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).
What is the current status of trial NCT04404660?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 153 participants. The study started on 2020-06-03. Estimated completion is 2029-06-30.
What conditions does trial NCT04404660 study?
This clinical trial studies the following conditions: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT04404660?
The interventions under investigation include: AUTO1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04404660?
This trial is sponsored by Autolus Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04404660 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04404660's enrollment target sits among peer trials
153 358th of 2000 higher than 1,642 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
RECRUITING · Phase 1
-
BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI